DAEWOONG CO.,LTD Logo

DAEWOONG CO.,LTD

A holding company in the biotech and healthcare sectors developing pharmaceuticals.

003090 | KO

Overview

Corporate Details

ISIN(s):
KR7003090008
LEI:
Country:
South Korea
Address:
경기 성남시 중원구 상대원동 223-23, 성남시

Description

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
투자판단관련주요경영사항(자회사의 주요경영사항)
Korean 14.9 KB
2025-09-05 00:00
투자판단관련주요경영사항(자회사의 주요경영사항)
Korean 9.0 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 3.7 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 4.0 MB
2025-07-30 00:00
투자판단관련주요경영사항(자회사의 주요경영사항)
Korean 9.5 KB
2025-06-02 00:00
기업지배구조보고서공시
Korean 708.5 KB
2025-05-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-05-16 00:00
주식등의대량보유상황보고서(일반)
Korean 162.0 KB
2025-05-16 00:00
최대주주등소유주식변동신고서
Korean 58.0 KB
2025-05-15 00:00
[기재정정]최대주주등소유주식변동신고서
Korean 54.8 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 2.1 MB
2025-05-14 00:00
[기재정정]최대주주등소유주식변동신고서
Korean 60.7 KB
2025-04-16 00:00
단기차입금증가결정(자회사의 주요경영사항)
Korean 11.5 KB
2025-04-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-04-01 00:00
주식등의대량보유상황보고서(약식)
Korean 62.4 KB

Automate Your Workflow. Get a real-time feed of all DAEWOONG CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAEWOONG CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAEWOONG CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.